ATE511655T1 - Verfahren zur auswertung eines myelounterdrückungszustands - Google Patents

Verfahren zur auswertung eines myelounterdrückungszustands

Info

Publication number
ATE511655T1
ATE511655T1 AT03737046T AT03737046T ATE511655T1 AT E511655 T1 ATE511655 T1 AT E511655T1 AT 03737046 T AT03737046 T AT 03737046T AT 03737046 T AT03737046 T AT 03737046T AT E511655 T1 ATE511655 T1 AT E511655T1
Authority
AT
Austria
Prior art keywords
patient
evaluation
methods
suppression condition
myelosuppressive
Prior art date
Application number
AT03737046T
Other languages
English (en)
Inventor
Rosalyn Blumenthal
David Goldenberg
Original Assignee
Ct For Molecular Medicine And Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct For Molecular Medicine And Immunology filed Critical Ct For Molecular Medicine And Immunology
Application granted granted Critical
Publication of ATE511655T1 publication Critical patent/ATE511655T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radar Systems Or Details Thereof (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03737046T 2002-06-14 2003-06-13 Verfahren zur auswertung eines myelounterdrückungszustands ATE511655T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/173,550 US7112409B2 (en) 1999-01-29 2002-06-14 Method of determining cytokine dosage for myelosuppressive state
PCT/US2003/018601 WO2003106967A2 (en) 2002-06-14 2003-06-13 Method of evaluating myelosuppressive state

Publications (1)

Publication Number Publication Date
ATE511655T1 true ATE511655T1 (de) 2011-06-15

Family

ID=29733378

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03737046T ATE511655T1 (de) 2002-06-14 2003-06-13 Verfahren zur auswertung eines myelounterdrückungszustands

Country Status (7)

Country Link
US (3) US7112409B2 (de)
EP (1) EP1585963B1 (de)
JP (1) JP2006501171A (de)
AT (1) ATE511655T1 (de)
AU (1) AU2003238023A1 (de)
CA (1) CA2489444A1 (de)
WO (1) WO2003106967A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112409B2 (en) * 1999-01-29 2006-09-26 Center For Molecular Medicine And Immunology Method of determining cytokine dosage for myelosuppressive state
CN101536006A (zh) * 2006-11-10 2009-09-16 皇家飞利浦电子股份有限公司 用于患者医疗的治疗计划的设备、方法、计算机可读介质
US20130022501A1 (en) * 2007-09-14 2013-01-24 University Of Medicine And Dentistry Of New Jersey Salivary Bioassay for Early Detection of Bone Loss
EP2310006A4 (de) * 2008-07-03 2012-04-25 Mayo Foundation Krebsbehandlung
US10445846B2 (en) 2011-04-14 2019-10-15 Elwha Llc Cost-effective resource apportionment technologies suitable for facilitating therapies
US9626650B2 (en) 2011-04-14 2017-04-18 Elwha Llc Cost-effective resource apportionment technologies suitable for facilitating therapies
ES2792062T3 (es) 2011-05-09 2020-11-06 Mayo Found Medical Education & Res Tratamientos contra el cáncer
US20130046153A1 (en) 2011-08-16 2013-02-21 Elwha LLC, a limited liability company of the State of Delaware Systematic distillation of status data relating to regimen compliance
CA2845621A1 (en) * 2011-09-13 2013-03-21 Basf Se Means and methods for assessing hematopoietic toxicity
US20130173295A1 (en) 2011-12-30 2013-07-04 Elwha LLC, a limited liability company of the State of Delaware Evidence-based healthcare information management protocols
US10559380B2 (en) 2011-12-30 2020-02-11 Elwha Llc Evidence-based healthcare information management protocols
US10475142B2 (en) 2011-12-30 2019-11-12 Elwha Llc Evidence-based healthcare information management protocols
US10679309B2 (en) 2011-12-30 2020-06-09 Elwha Llc Evidence-based healthcare information management protocols
US10528913B2 (en) 2011-12-30 2020-01-07 Elwha Llc Evidence-based healthcare information management protocols
US10340034B2 (en) 2011-12-30 2019-07-02 Elwha Llc Evidence-based healthcare information management protocols
US10552581B2 (en) 2011-12-30 2020-02-04 Elwha Llc Evidence-based healthcare information management protocols
WO2013155129A1 (en) * 2012-04-11 2013-10-17 Indiana University Research And Technology Corporation System and method for concurrent chemotherapy and radiotherapy cancer treatment, and chemotherapeutic agent detection strategy
ES2899643T3 (es) 2012-10-01 2022-03-14 Mayo Found Medical Education & Res Tratamientos para el cáncer
AU2015274408A1 (en) 2014-06-13 2017-01-12 Mayo Foundation For Medical Education And Research Treating lymphomas
US10213513B2 (en) 2014-06-16 2019-02-26 Mayo Foundation For Medical Education And Research Treating myelomas
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
US11571469B2 (en) 2016-01-07 2023-02-07 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
US11351254B2 (en) 2016-02-12 2022-06-07 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
WO2017165439A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
CA3018341A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
EP3506950A1 (de) 2016-09-01 2019-07-10 Mayo Foundation for Medical Education and Research Gegen t-zell-karzinome gerichtete verfahren und zusammensetzungen
CA3035378A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Carrier-pd-l1 binding agent compositions for treating cancers
EP3509635A1 (de) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Verfahren zur behandlung von dreifach negativem brustkrebs unter verwendung von zusammensetzungen aus antikörpern und trägerproteinen
AU2017324335A1 (en) 2016-09-06 2019-03-28 Mayo Foundation For Medical Education And Research Methods of treating PD-L1 expressing cancer
EP3509643A1 (de) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Paclitaxel-albumin-bindende wirkstoffzusammensetzungen und verfahren zur verwendung und herstellung davon

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3888224T2 (de) 1987-04-24 1994-07-21 Teijin Ltd Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung.
US5360716A (en) * 1988-10-24 1994-11-01 Otsuka Pharmaceutical Co., Ltd. Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α
US5223395A (en) * 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
IT1249708B (it) 1991-09-23 1995-03-09 Tecnogen Scpa Metodo per la determinazione del fattore di necrosi tumorale (tnf) in forma biologicamente attiva.
CA2089304A1 (en) 1992-02-20 1993-08-21 Linda Anderson-Mauser Diagnosis of candida vaginitis by detecting d-arabinitol in vaginal fluid
ATE196775T1 (de) 1993-05-19 2000-10-15 Schering Corp Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
JPH11510479A (ja) 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
EP0846169B1 (de) 1995-08-04 2003-03-19 Lek, Tovarna Farmacevtskih in Kemicnih Izdelkov, D.D. Monoklonale antikörper gegen lösliche tnf-alpha rezeptoren p55 und p75 als auch gegen tnf-alpha und dessen analogen
US6649352B1 (en) 1999-01-29 2003-11-18 Center For Molecular Medicine And Immunology Method of evaluating myelosuppressive state
US7112409B2 (en) 1999-01-29 2006-09-26 Center For Molecular Medicine And Immunology Method of determining cytokine dosage for myelosuppressive state
AU2001236005A1 (en) * 2000-02-29 2001-09-12 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time

Also Published As

Publication number Publication date
WO2003106967A2 (en) 2003-12-24
US20060193770A1 (en) 2006-08-31
EP1585963A2 (de) 2005-10-19
JP2006501171A (ja) 2006-01-12
US7112409B2 (en) 2006-09-26
CA2489444A1 (en) 2003-12-24
EP1585963A4 (de) 2006-11-29
AU2003238023A1 (en) 2003-12-31
US7465551B2 (en) 2008-12-16
EP1585963B1 (de) 2011-06-01
US20060088891A1 (en) 2006-04-27
WO2003106967A9 (en) 2004-02-26
US7279289B2 (en) 2007-10-09
WO2003106967A3 (en) 2005-11-17
US20070036749A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
ATE511655T1 (de) Verfahren zur auswertung eines myelounterdrückungszustands
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
ATE529125T1 (de) Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung
AU8116301A (en) Methods for treating autoimmune and chronic inflammatory conditions using antagonists of cd30 or cd30l
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE602004031462D1 (de) Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
EP1712239A3 (de) Interleukin-1 Inhibitoren zur Behandlung von Erkrankungen
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
ATE556711T1 (de) Verfahren zur verbesserung der hautqualität
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
NO20072055L (no) Fremgangsmater og sammensetninger for behandling av flaviviruser, pestiviruser og hepacivirus
CY1111263T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
TW200606162A (en) Pyrazolopyridine derivatives
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
IL151628A0 (en) Combination therapies with vascular damaging activity
DK1545537T3 (da) Alfa-7-nikotinreceptoragonister og statiner i kombination
EA201000630A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови
MXPA05007287A (es) Formulacion y metodos para el tratamiento de trombocitemia.
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
TW200611693A (en) GPR35 and modulators thereof for the treatment of metabolic-related disorders

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties